NCT06042725 - MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions

Multiple Myeloma

Interventions

PROCEDURE

Biospecimen Collection

Undergo optional collection of blood samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Computed Tomography

Undergo PET/CT

BIOLOGICAL

Daratumumab

Given SC

DRUG

Dexamethasone

Given PO

DRUG

Lenalidomide

Given PO

PROCEDURE

Low Dose Computed Tomography of the Whole Body

Undergo WBLDCT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Venetoclax

Given PO

PROCEDURE

X-Ray Imaging

Undergo x-rays

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester